| Document |
Document Title |
|
WO/2024/097206A1 |
The present invention relates to Compound (A), pharmaceutically acceptable salts thereof, methods of making, and use thereof optionally in combination with one or more additional therapeutic agents for the treatment of disease.
|
|
WO/2024/095734A1 |
This fluorine-containing heterocyclic compound production method is for obtaining a compound represented by formula (2) through intramolecular cyclization of a compound represented by formula (1). X1 represents a hydrogen atom, a fluorin...
|
|
WO/2024/097205A1 |
The present invention relates to Compound (A), pharmaceutically acceptable salts thereof, methods of making, and use thereof for the treatment of disease.
|
|
WO/2024/092369A1 |
A method for promoting fertility enhancement in a mammal is provided, comprising administering to the mammal a weight loss agent, a mitochondria-enhancing agent and a fertility support agent. Compositions for fertility enhancement are al...
|
|
WO/2024/097910A1 |
Aspects of the present disclosure relate to the use of CBD for treating metabolic dysfunction and associated conditions.
|
|
WO/2024/088237A1 |
Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
|
|
WO/2024/088109A1 |
Provided are an aryl heterocyclic compound, a preparation method therefor, and a use thereof, and the structural formula of the aryl heterocyclic compound is as shown in formula (I). The provided compound has a monoaminergic system regul...
|
|
WO/2024/087261A1 |
A method for extracting, separating, and purifying 8-prenylnaringenin from hops, comprising the steps of: S1, performing first extraction on a hop raw material by means of supercritical carbon dioxide to obtain first hop extract residues...
|
|
WO/2024/088287A1 |
A decarboxylation method for industrial hemp flowers and leaves. The method uses a vacuum microwave drying device to carry out the decarboxylation of hemp flowers and leaves, and comprises the steps of crushing hemp flowers and leaves, s...
|
|
WO/2024/089023A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
|
|
WO/2024/092209A1 |
Described are compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).
|
|
WO/2024/082757A1 |
Provided are the use of chlorflavonin and derivatives thereof, in particular the use thereof in inhibiting the growth of microorganisms and inhibiting the growth of plants. Also provided are genes associated with the synthesis of flavone...
|
|
WO/2024/083210A1 |
Among other things, the present disclosure provides compounds, e.g., of formula I or salts thereof. In some embodiments, the present disclosure provides methods for modulating MRGPRX4 activity. In some embodiments, the present disclosure...
|
|
WO/2024/081904A1 |
This disclosure provides compounds of Formula (I), Formula (II), Formula (III), and pharmaceutically acceptable salts of any of the foregoing, that inhibit PI3Kα. These compounds are useful for treating diseases such as cancer in a subj...
|
|
WO/2024/073383A1 |
Disclosed herein are substituted compounds of formula (I), salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.
|
|
WO/2024/067718A1 |
The present invention relates to an ether-functionalized coumarin oxime ester compound of formula (I), wherein the variables therein are as defined in the description. The compound has good photosensitive absorption in the range of 300-5...
|
|
WO/2024/069589A1 |
Hexahydrocannabinol (HHC), hexahydrocannabidiol (H4CBD), and hexahydrocannabidivarin (H4CBDV) derivatives are disclosed. Also disclosed are pharmaceutical compositions comprising such derivatives. Further described are methods of use the...
|
|
WO/2024/071062A1 |
Provided is a compound that further improves the performance of an organic EL element, said compound being represented by formula (1) or (2). (Each symbol in the formulas is as defined in the description.)
|
|
WO/2024/071980A1 |
The present invention pertains to: a xanthene derivative compound having a high refractive index; and a method for producing same. More specifically, the present invention pertains to: a high refractive index monomer that has a xanthene-...
|
|
WO/2024/071372A1 |
The present disclosure provides an oxidative cleavage method of a Trolox amide. More particularly, the disclosure provides a method for producing a compound of formula I, the method including a step for contacting a compound of formula I...
|
|
WO/2024/066916A1 |
Disclosed are an aromatic amine compound comprising a quaterphenyl structure and an organic electroluminescent device comprising the same. The aromatic amine compound has a structure represented by formula (I). The compound has the follo...
|
|
WO/2024/072930A1 |
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include...
|
|
WO/2024/062149A1 |
The present invention relates to compounds, especially to conjugates and derivatives of alternariol labelled at specific positions in the molecule, suitable for the production of antibodies with a high affinity for alternariol. Likewise,...
|
|
WO/2024/064734A1 |
Provided herein are crystalline forms of 3-({[(4R)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro
-2H-1-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid, L-lysine salt, as histone demethylase inhibitors. Also provided herein a...
|
|
WO/2024/055118A1 |
The present disclosure relates to a use of minor cannabinoids in the management or treatment of a seizure disorder in a patient. Minor cannabinoids include cannabichromene (CBC), cannabichromenic acid (CBCA), cannabigerol (CBG), cannabig...
|
|
WO/2024/052939A1 |
A nanocomposite for treating bacterial urinary tract infections is disclosed. Said nanocomposite broadly comprises: an about 10 mg/mL of zinc oxide nanoparticles; an about 2 mg/mL of type-A procyanidin; and methanol. Said zinc oxide nano...
|
|
WO/2024/051778A1 |
Provided herein are compounds having a Formula II-4, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds in inhibiting PI3K in a cell, or in treati...
|
|
WO/2024/047529A1 |
An example of a water dispersible emulsion is provided. The water dispersible emulsion includes a cannabinoid at about 0.1-5.0% (w/w) collectively. In addition, the water dispersible emulsion includes an edible oil at about 0.1-15.0% (w/...
|
|
WO/2024/046542A1 |
An indeno-fused naphthopyran having the core skeletal structure (I): (I) wherein R1 is a substituted or unsubstituted alkyl group; R2 is substituted or unsubstituted amino; substituted or unsubstituted alkyl; substituted or unsubstituted...
|
|
WO/2024/047227A1 |
The present invention relates to compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical c...
|
|
WO/2024/043108A1 |
A photocurable composition containing a coloring agent, a radical polymerization initiator represented by formula (1) and a radically polymerizable compound; a method for producing a cured film using the photocurable composition; a film;...
|
|
WO/2024/044616A1 |
The present disclosure provides for polyfunctionalized biaryls having complex biaryl architectures, methods of making polyfunctionalized biaryls, and the like. The present disclosure provides for the cine-ipso-difunctionalization transfo...
|
|
WO/2024/040037A1 |
Provided herein are extracts of Scutellaria ocmulgee and methods of reducing body fat and/or body fat gain in a subject including administering to the subject a therapeutically effective amount of an extract of Scutellaria ocmulgee, wher...
|
|
WO/2024/039330A1 |
The present invention relates to the formation of therapeutic combinations of the natural hispidulin molecule for use in the treatment of proliferative vitreoretinopathy (PVR) by formulating it with single and/or 5-fluorouracil (5-FU) or...
|
|
WO/2024/033667A1 |
The present invention relates to visible light sensitive photoremovable protecting groups and their parent compounds X including a xanthene, xanthenium or related cores, represented by formula (Xa): (Xa) wherein the substituents are as d...
|
|
WO/2024/028516A1 |
A synthesis method for the preparation of a cannabinoid selected from cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), comprising the steps of: a) dissolving olivetol in dichloromethane (DCM) with stirring; b) adding FeCl3 * 6H2O as...
|
|
WO/2024/029580A1 |
The present disclosure at least addresses the problem of providing a feature for accelerating activation of autophagy. The present invention provides an autophagy-activation-accelerating composition containing an urolithin and trans-resv...
|
|
WO/2024/023169A1 |
Disclosed are substituted tetrahydro-(5H)-chromen-5-one and hexahydro-(5H)-chromen- 5-one derivatives of formula (I) possessing woody, peppery notes which is reminiscent of Rotundone. A method of their production and consumer products co...
|
|
WO/2024/018420A1 |
Compositions comprising 0.1-50 % delta-9-tetrahydrocannabinol and/or cannabidiol in forms suitable for continuous delivery and use thereof in the treatment of a variety of diseases and pathological disorders are disclosed. In preferred e...
|
|
WO/2024/017815A1 |
The present invention relates to a specific multicomponent crystalline system (co- crystal) comprising Urolithin A as one of the components produced by a specific process.
|
|
WO/2024/017814A1 |
The present invention relates to a specific multicomponent crystalline system (co- crystal) comprising Urolithin A as one of the components produced by a specific process.
|
|
WO/2024/008833A1 |
A prodrug kit for multifactorial dynamic chemotherapy comprises N different small-molecule- drug-conjugates selected from the group comprising Si = Fci―Li―Cti with i = 1, 2, 3, …., 360 wherein 2 ≤ N ≤ 360, Fci is a moiety that ...
|
|
WO/2024/009260A1 |
The present invention refers to a method for the recovery of ellagic acid from streams of lignocellulosic materials manufacturing industries, preferably from cellulosic pulp mill streams, such as cooking liquors and bleaching line efflue...
|
|
WO/2024/007726A1 |
The present invention relates to a small-molecule compound, and the use thereof as a cosmetic active ingredient and a preparation method therefor. The small-molecule compound is a compound as shown in the following general formula (I). R...
|
|
WO/2024/006896A1 |
Aspects of the present disclosure relate to the use of the synthetic, hydrogenated CBD (H4CBD) for treating metabolic dysfunction and associated conditions.
|
|
WO/2024/001115A1 |
Disclosed are a kaurane tetracyclic diterpenoid derivative, a preparation method therefor and a medical use thereof. The present invention specifically relates to a novel derivative of a kaurane tetracyclic diterpenoid compound shown in ...
|
|
WO/2024/003906A1 |
The present invention provides cannabinoid derivatives, pharmaceutical compositions comprising same, and methods of use thereof as medicaments.
|
|
WO/2023/247416A1 |
The present invention relates to compounds of the tetraarylbenzidine- type, bearing specific (het)aryl groups at the nitrogen atoms bound to the 1,1 '-biphenylene backbone, and to methods for their preparation. The invention further rela...
|
|
WO/2023/244646A1 |
The present disclosure is related to the separation of chemical species using multiple liquid phases. The present disclosure is also related to the continuous liquid- liquid chromatographic separation of chemical species using multiple l...
|
|
WO/2023/240348A1 |
A pharmaceutical composition in the form of a compressed tablet for oral administration is provided. The composition has an intragranular portion comprising: a first porous solid carrier comprising a physiologically acceptable salt that ...
|
